PTC-028

• CAT Number: I014656
• CAS Number: 1782970-28-8
• Molecular Formula: C19H12F5N5
• Molecular Weight: 405.33
• Purity: ≥95%
• Synonyms: PTC-028; PTC028; PTC 028;2-Pyrazinamine, 6-(5,6-difluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]-
• Target: Apoptosis
• Solubility: Soluble in DMSO
• IUPAC Name: 6-(5,6-difluoro-2-methylbenzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]pyrazin-2-amine
• InChI: InChI=1S/C19H12F5N5/c1-10-26-15-6-13(20)14(21)7-16(15)29(10)18-9-25-8-17(28-18)27-12-4-2-11(3-5-12)19(22,23)24/h2-9H,1H3,(H,27,28)
• InChIKey: JEZGPBWIZWPDHP-UHFFFAOYSA-N
• SMILES: CC1=NC2=CC(=C(C=C2N1C3=NC(=CN=C3)NC4=CC=C(C=C4)C(F)(F)F)F)F

PTC-028（Cat No.:I014656）is an experimental small molecule drug being developed for the treatment of cancer, particularly for targeting mutant forms of the Kirsten rat sarcoma viral oncogene (KRAS). KRAS mutations are common in several cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. PTC-028 works by inhibiting mutant KRAS activity, which plays a key role in cancer cell survival and proliferation. Preclinical studies suggest that PTC-028 may selectively target KRAS-driven tumors, offering a novel therapeutic strategy. Clinical trials are ongoing to assess its safety, efficacy, and potential in cancer treatment.